Zoetis Inc. $ZTS Shares Sold by Cantillon Capital Management LLC

Cantillon Capital Management LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,205,716 shares of the company’s stock after selling 13,379 shares during the quarter. Cantillon Capital Management LLC owned about 0.27% of Zoetis worth $176,420,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. REAP Financial Group LLC lifted its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the period. NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. ORG Partners LLC increased its stake in shares of Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after acquiring an additional 84 shares during the period. Finally, Financial Consulate Inc. bought a new stake in Zoetis during the third quarter worth approximately $39,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 0.6%

Shares of NYSE:ZTS opened at $124.35 on Friday. The firm has a 50 day simple moving average of $123.51 and a 200 day simple moving average of $138.66. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The company has a market cap of $54.80 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 2.17 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Piper Sandler reissued a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 13th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research report on Monday, December 15th. Finally, Barclays started coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.